For premenopausal patients with HR+/HER2- metastatic breast cancer (mBC), treatment choices are complex due to physiological characteristics, tumor properties, and treatment tolerance. Many patients receive chemotherapy early due to endocrine resistance and concerns about rapid tumor progression, with capecitabine being a commonly used regimen. At the 2024 ASCO conference, the latest updated survival results from the Young-PEARL randomized phase II study were presented. The study evaluated the safety and clinical anti-tumor efficacy of palbociclib combined with GnRHa and exemestane versus capecitabine in premenopausal HR+/HER2- mBC patients. Oncology Frontier interviewed the primary investigator, Professor Yeon Hee Park from Samsung Medical Center in Seoul, Korea, to discuss the study's background, methods, main results, and clinical significance. This comparative study provides significant insights into endocrine therapy for HR+/HER2- advanced breast cancer, offering a valuable alternative to traditional chemotherapy.

In the field of breast cancer treatment, gene testing for early-stage breast cancer has become a vital component of precision medicine. By deeply analyzing the genetic expression profiles of patients, we can more accurately predict disease progression and develop more personalized adjuvant treatment strategies. However, how is gene testing currently applied in clinical practice, and what challenges remain? Oncology Frontier invited Professor Qiang Zhang from Liaoning Cancer Hospital & Institute to discuss the FLEX study presented at the 2024 ASCO conference.

Editor's Note: From July 5-7, 2024, the 2024 Chinese Clinical Oncology Annual Progress Seminar (BOC) and Beast of ASCO® 2024 China were grandly held in Guangzhou. On the 6th, a…

On June 27, 2024, Nature Communications published the results of a phase 1 clinical trial conducted by Professor Binghe Xu, an academician of the Chinese Academy of Engineering, and his joint team. The study focuses on a novel HER2 antibody-drug conjugate (ADC), FS-1502, which offers a potential new treatment option for HER2-positive breast cancer patients.

The mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) was held from June 28-30, 2024, in Shanghai. Young talents from across the country gathered to share experiences and discuss the future. Several experts shared their clinical and translational research experiences during the conference. Clinical research derived from practice is crucial for enhancing medical innovation, bridging the gap between basic research and clinical practice, and improving the medical research funding landscape. Oncology Frontier invited Professor Wenxing Qin from Fudan University Shanghai Cancer Center to share his experiences in clinical and translational research, balancing research, life, and clinical work, and choosing research directions.

In recent years, there have been two significant changes in the field of liver cancer. On the one hand, with the development of treatment technologies, the prognosis of liver cancer patients has significantly improved, shedding its title as the "king of cancers." On the other hand, China's rapid advancements in liver cancer diagnosis and research have contributed a series of "Chinese solutions" and "Chinese wisdom" to global liver cancer prevention and treatment. On the eve of the "2024 Annual Progress Seminar on Chinese Clinical Oncology (BOC) and Best of ASCO 2024 China," Oncology Frontier interviewed the renowned clinical oncology expert, Professor Shukui Qin from The First Affiliated Hospital of China Pharmaceutical University (Nanjing Tianyinshan Hospital), to review China's achievements in liver cancer prevention and treatment research and to share the latest advances in systemic therapy for liver cancer.

Circulating tumor DNA (ctDNA) is a novel liquid biopsy method that detects tumor-specific DNA mutations in the blood of breast cancer patients, helping to identify high-risk patients prone to recurrence and metastasis. Its prognostic value has been confirmed in multiple studies. At the 2024 ASCO conference, a study (Abstract LBA507) further analyzed the MonarchE study population, confirming that ctDNA testing has predictive value for recurrence risk in HR+/HER2-, lymph node-positive high-risk early-stage breast cancer patients. Oncology Frontier invited Professor Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University  to provide an introduction and commentary.

With the continuous emergence of novel therapeutic agents, treatment strategies for advanced melanoma have evolved from traditional chemotherapy and radiotherapy to include immunotherapy, targeted therapy, chemotherapy, and their combinations. Global researchers are constantly exploring and optimizing treatment options for first-line therapy in advanced melanoma. At the 2024 American Society of Clinical Oncology (ASCO 2024) Annual Meeting, several oral presentations showcased the latest developments in this field. Oncology Frontier is honored to have Professor Chuanliang Cui from Peking University Cancer Hospital share insights on these studies.

In recent years, with the advancement of innovative mechanisms and technologies, antibody-drug conjugates (ADCs) have become a research hotspot. ADC drugs have further promoted clinical development, clinical translation, and patient treatment outcomes. Recently, the high-level closed-door seminar "Planning and Action, Breaking Through the Billion-Dollar ADC Market," hosted by the Oriental Clinical Oncology Research Center, China Pharmaceutical University, and Shanghai Gaobo Oncology Hospital Affiliated to China Pharmaceutical University, was successfully held in Shanghai. Oncology Frontier invited Vice President Yong Yang of China Pharmaceutical University, President Jin Li of Shanghai Gaobo Oncology Hospital Affiliated to China Pharmaceutical University, and Executive President Chen Feng of Shanghai Gaobo Oncology Hospital Affiliated to China Pharmaceutical University to a roundtable discussion. They jointly explored the development trends of ADCs in China and collaborated to plan the future blueprint for ADCs.